pre-IPO PHARMA

COMPANY OVERVIEW

Forbius is a clinical-stage protein engineering company that designs and develops novel biologics for the treatment of fibrosis and cancer. Our current focus is on the development of agents that target the transforming growth factor-beta (TGF-beta) and the epidermal growth factor receptor (EGFR) pathways.


LOCATION

  • Austin, TX, USA
  • Montréal, Quebec, Canada

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://forbius.com


    CAREER WEBSITE

    https://forbius.com/careers


    SOCIAL MEDIA


    INVESTORS

    lumira-ventures


    PRESS RELEASES


    Sep 21, 2020

    Bristol Myers Squibb Completes Acquisition of Forbius


    Aug 24, 2020

    Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio


    Nov 18, 2019

    Forbius to Present at Jefferies 2019 London Healthcare Conference


    Nov 8, 2019

    Forbius Completes Phase 1 Oncology Dose-Escalation with AVID200, First-in-Class TGF-beta 1 and 3 Inhibitor: Well Tolerated, Target Inhibition Demonstrated at All Dose Levels, Data Reported at SITC


    Nov 5, 2019

    SITC 2019: Forbius to Report Phase 1a Oncology Clinical Data with AVID200, First-in-Class TGF-beta 1 and 3 Inhibitor, in Late-Breaking Poster Presentation


    For More Press Releases


    Google Analytics Alternative